SD | Shutterstock
The reviews conclude that longer-term, independently funded studies are crucial for guiding both medical practice and public health policy. A clearer understanding of sustained benefits and risks will help define the role of GLP-1 receptor agonists in long-term weight management. Commissioned by the World Health Organization, these findings will inform new WHO guidelines on the use of GLP-1 receptor agonists for obesity treatment.